Heron Therapeutics Inc (HRTX) on Focus After Raising In Today’s Session

September 17, 2017 - By Michael Collier

The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! The stock increased 5.12% or $0.75 on September 15, reaching $15.4. About 1.20M shares traded or 142.29% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 20.92% since September 17, 2016 and is downtrending. It has underperformed by 37.62% the S&P500.
The move comes after 7 months positive chart setup for the $833.74 million company. It was reported on Sep, 17 by Barchart.com. We have $16.02 PT which if reached, will make NASDAQ:HRTX worth $33.35 million more.

Investors wait Heron Therapeutics Inc (NASDAQ:HRTX) to report on November, 14. its quarterly earnings Wall Street analysts expect $-0.87 EPS, up $0.37 or 29.84 % from last year’s $-1.24 same quarter earnings. Heron Therapeutics Inc’s Wall Street analysts see 8.75 % negative EPS growth, taking into account the $-0.80 EPS reproted in the previous quarter,

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Among 10 analysts covering Heron Therapeutics (NASDAQ:HRTX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 19 analyst reports since August 3, 2015 according to SRatingsIntel. Aegis Capital initiated the shares of HRTX in report on Wednesday, October 26 with “Buy” rating. The rating was initiated by Bank of America with “Buy” on Wednesday, September 2. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) has “Outperform” rating given on Wednesday, September 23 by Leerink Swann. The rating was maintained by Jefferies with “Buy” on Wednesday, September 23. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Jefferies on Tuesday, August 15. The company was maintained on Friday, May 26 by Cowen & Co. Brean Capital maintained Heron Therapeutics Inc (NASDAQ:HRTX) on Monday, August 10 with “Buy” rating. On Thursday, August 10 the stock rating was maintained by Noble Financial with “Buy”. The firm has “Buy” rating by Cowen & Co given on Thursday, August 3. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Lake Street on Thursday, December 10.

More notable recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Heron Therapeutics: CINV Franchise Provides Valuation Floor, Significant …” on February 04, 2017, also Seekingalpha.com with their article: “Heron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market” published on July 10, 2017, Seekingalpha.com published: “Heron Therapeutics: Giving A ‘Thumbs Up’ To This ~$14 Biopharma Stock” on February 27, 2017. More interesting news about Heron Therapeutics Inc (NASDAQ:HRTX) were released by: Seekingalpha.com and their article: “Heron Therapeutics: Our Next Pick” published on August 14, 2017 as well as Reuters.com‘s news article titled: “BRIEF-Heron Therapeutics appoints Robert Hoffman as CFO” with publication date: April 24, 2017.

Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has market cap of $833.74 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.